Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSL ( (AU:CSL) ) has provided an announcement.
CSL Limited held its 2025 Annual General Meeting in Melbourne, where key updates were provided regarding financial projections for 2026-2028 and a proposal to demerge CSL Seqirus. The meeting underscored the company’s strategic direction amidst current market challenges, emphasizing its commitment to sustainable and profitable growth. The AGM also highlighted changes in board membership, with some directors retiring and others standing for election, reflecting a robust governance structure.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$265.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biotechnology company based in Melbourne, Australia, primarily engaged in the development and delivery of innovative medicines that save lives, protect public health, and help people with life-threatening medical conditions. The company focuses on biopharmaceuticals, vaccines, and plasma protein therapeutics.
Average Trading Volume: 1,202,202
Technical Sentiment Signal: Sell
Current Market Cap: A$103.1B
See more insights into CSL stock on TipRanks’ Stock Analysis page.